Transdermal and dermal delivery of adefovir: effects of pH and permeation enhancers.
The objective of this work was to investigate feasibility of transdermal and dermal delivery of adefovir (9-(2-phosphonomethoxyethyl)adenine), a broad-spectrum antiviral from the class of acyclic nucleoside phosphonates. Transport of 2% adefovir through and into porcine skin and effects of various solvents, pH, and permeation enhancers were studied in vitro using Franz diffusion cell. From aqueous donor samples, adefovir flux through the skin was 0.2-5.4 microg/cm2/h with greatest permeation rate at pH 7.8. The corresponding adefovir skin concentrations reached values of 120-350 microg/g of tissue. Increased solvent lipophilicity resulted in higher skin concentration but had only minor effect on adefovir flux. A significant influence of counter ions on both transdermal and dermal transport of adefovir zwitterion was observed at pH 3.4. Permeation enhancer dodecanol was ineffective, 1-dodecylazepan-2-one (Azone) and dodecyl 2-(dimethylamino)propionate (DDAIP) showed moderate activity. The highest adefovir flux (11.3+/-3.6 microg/cm2/h) and skin concentration (1549+/-416 microg/g) were achieved with 1% Transkarbam 12 (5-(dodecyloxycarbonyl)pentylammonium 5-(dodecyloxycarbonyl)pentylcarbamate) at pH 4. This study suggests that, despite its hydrophilic and ionizable nature, adefovir can be successfully delivered through the skin.
Vávrová
Katerina
K
Centre for New Antivirals and Antineoplastics, Faculty of Pharmacy in Hradec Králové, Charles University in Prague, Prague, Czech Republic. katerina.vavrova@faf.cuni.cz <katerina.vavrova@faf.cuni.cz>
Lorencová
Katerina
K
Klimentová
Jana
J
Novotný
Jakub
J
Holý
Antoni N
AN
Hrabálek
Alexandr
A
D000225:Adenine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D000279:Administration, Cutaneous; D000998:Antiviral Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D002851:Chromatography, High Pressure Liquid; D016503:Drug Delivery Systems; D005079:Excipients; D006801:Humans; D006863:Hydrogen-Ion Concentration; D066298:In Vitro Techniques; D063065:Organophosphonates / Q000008:administration & dosage / Q000493:pharmacokinetics*; D010539:Permeability; D012869:Skin Absorption / Q000187:drug effects; D012997:Solvents
D000998:Antiviral Agents; D005079:Excipients; D063065:Organophosphonates; D012997:Solvents; C053001:adefovir; D000225:Adenine